Ibuprofen

Introduction Overview

Generic Name

ibuprofen

Brand Name

Advil, Genpril, IBU, Midol IB, Motrin IB, Proprinal, Smart Sense Children's Ibuprofen

Dosage Form

oral capsule, oral suspension, oral tablet, chewable tablet

Drug Class

Nonsteroidal anti-inflammatory drugs (NSAIDs)

Pharmacokinetics

Absorption:
Ibuprofen is rapidly absorbed from the gastrointestinal tract following oral administration. Peak plasma concentrations are typically reached within 1 to 2 hours under fasting conditions. Food intake can delay the rate of absorption, thus prolonging the time to peak concentration, but does not significantly affect the extent of absorption, with bioavailability remaining generally consistent. The drug has high oral bioavailability approximately around 80-90%, ensuring effective systemic exposure. The acidic properties of ibuprofen facilitate rapid dissolution and absorption in the stomach and upper small intestine. Clinical implications include the potential for quicker onset of analgesic and antipyretic effects when taken on an empty stomach, balanced against the risk of gastrointestinal irritation.

Distribution:
Ibuprofen is extensively distributed throughout body tissues and has a volume of distribution ranging approximately from 0.1 to 0.2 L/kg. It is highly bound to plasma proteins, primarily albumin, with binding exceeding 99%, which limits free drug availability but prolongs circulation time. The ability to cross the blood-brain barrier is limited, but sufficient CNS penetration occurs to exert analgesic effects. Distribution into breast milk is minimal, making it generally safe during breastfeeding with caution. The binding profile may be influenced by other highly protein-bound drugs, altering pharmacodynamics and necessitating monitoring for drug interactions.

Metabolism:
Ibuprofen undergoes almost complete hepatic metabolism primarily through cytochrome P450 enzymes, especially CYP2C9. The drug is extensively metabolized to inactive hydroxylated and carboxylated derivatives, which are then conjugated before excretion. Genetic polymorphisms in CYP2C9 may affect metabolism rate and influence individual response and risk of adverse effects. Drug interactions influencing CYP2C9 activity can alter ibuprofen plasma levels, changing efficacy and toxicity risk. Hepatic impairment may reduce metabolism, prolonging half-life and requiring dose adjustment.

Elimination:
Ibuprofen and its metabolites are eliminated primarily through renal excretion, with approximately 90% of the administered dose excreted in the urine, mainly as inactive metabolites and less than 1% as unchanged drug. The elimination half-life of ibuprofen is approximately 1.8 to 2 hours in healthy adults, contributing to the need for dosing every 4 to 6 hours. Renal impairment can reduce clearance, leading to accumulation and increased risk of toxicity. Additionally, ibuprofen's effect on renal prostaglandin synthesis may impact kidney function, particularly in susceptible populations such as those with pre-existing renal disease or volume depletion. Biliary elimination is minimal.

Dosage Forms

Available Dosage Forms:
- Oral capsules: 200 mg
- Oral suspension (liquid): 100 mg/5 mL; 50 mg/1.25 mL
- Oral tablets (immediate release): 100 mg; 200 mg; 400 mg; 600 mg; 800 mg
- Oral chewable tablets: 50 mg; 100 mg

Dosages for Adults and Adolescents:
Adult dosing typically starts at 200 to 400 mg orally every 4 to 6 hours as needed, with maximum single doses of 800 mg and maximum daily doses of 3200 mg (4 times 800 mg). For mild to moderate pain, lower doses and less frequent administration are recommended to minimize adverse effects. In adults with osteoarthritis or rheumatoid arthritis, longer-term dosing with 1200 to 3200 mg daily in divided doses may be used under medical supervision.

Specific Patient Populations:
In pediatric patients aged 6 months and older, dosing is weight-based, generally 5 to 10 mg/kg per dose every 6 to 8 hours, not to exceed 40 mg/kg per day. Special considerations apply in infants and those with renal or hepatic impairment, requiring dose adjustment or avoidance. Ibuprofen is contraindicated in neonates under 6 months without medical advice. Pregnant women, particularly in the third trimester (>20 weeks gestation), should avoid use due to risks of fetal cardiovascular and renal effects. The elderly may require dosage adjustments due to increased risk of adverse gastrointestinal and renal effects. The oral suspension is preferred for children to allow accurate dosing. Chewable tablet formulations improve compliance in pediatric patients capable of chewing solid forms.

Mechanism Of Action

Ibuprofen is a nonsteroidal anti-inflammatory drug (NSAID) that exerts its therapeutic effects primarily through the non-selective inhibition of cyclooxygenase (COX) enzymes, COX-1 and COX-2. By inhibiting these enzymes, ibuprofen blocks the conversion of arachidonic acid into prostaglandins and thromboxanes, which are mediators responsible for inflammation, pain, fever, and platelet aggregation. This reduction in prostaglandin synthesis leads to diminished inflammatory responses and relief of associated symptoms.

At the cellular level, ibuprofen decreases prostaglandin-mediated sensitization of nociceptors, thereby lowering the perception of pain. Its antipyretic effect resides in its action on the hypothalamic heat-regulating center, where it promotes heat dissipation through vasodilation and sweating by modulating prostaglandin E2 production. The drug also inhibits platelet aggregation transiently by reducing thromboxane A2 production, but this is less pronounced compared to aspirin.

Biochemically, the non-selective inhibition of both COX-1 and COX-2 enzymes by ibuprofen results in its therapeutic benefits as well as adverse effects. While COX-2 inhibition mediates the desired anti-inflammatory and analgesic effects, COX-1 inhibition impacts gastric mucosal protection and platelet function, accounting for gastrointestinal and bleeding side effects. Research evidence highlights ibuprofen’s reversible binding to COX enzymes, contrasting with aspirin’s irreversible inhibition, which confers differences in onset and duration of action and side effect profiles.

Clinical studies consistently demonstrate ibuprofen’s efficacy in managing mild to moderate pain conditions such as headaches, dental pain, musculoskeletal aches, and dysmenorrhea, as well as reducing fever and inflammation in arthritis. Comparative clinical trials with other NSAIDs reveal that ibuprofen provides rapid onset of symptom relief with a favorable safety and tolerability profile at recommended doses.

Pharmacological Actions

Nonsteroidal anti-inflammatory action via inhibition of prostaglandin synthesis.
Analgesic effects by reducing peripheral sensitization of nociceptors.
Antipyretic action through hypothalamic thermoregulation.
Reversible inhibition of cyclooxygenase enzymes COX-1 and COX-2.
Mild antiplatelet activity through thromboxane A2 inhibition.
Reduction of inflammation in arthritis, musculoskeletal injuries, and menstrual cramps.
Modulation of inflammatory mediators leading to decreased redness, swelling, and pain.
Temporary relief of fever associated with infections.
Minimal central nervous system penetration leading to low CNS side effects.
Competitive binding to COX enzymes resulting in short duration of action.
No significant immunosuppressive activity, preserving normal immune responses.
Lack of accumulation due to short elimination half-life.
Possible gastric mucosal irritation from COX-1 inhibition.
Reduction of prostaglandin-mediated vasodilation impacting renal function in susceptible patients.
Decreased production of inflammatory eicosanoids contributing to overall symptom control.

Therapeutic Or Clinical Uses

Management of mild to moderate pain including headache, toothache, and musculoskeletal pain.
Treatment of inflammation and pain associated with osteoarthritis and rheumatoid arthritis.
Relief of dysmenorrhea (menstrual cramps).
Reduction of fever in febrile illnesses in adults and children over 6 months.
Management of minor injuries such as sprains and strains.
Symptomatic relief in back pain and chronic myofascial pain.
Adjunctive treatment in dental pain and postoperative pain scenarios.
Short-term use for inflammatory conditions requiring non-opioid analgesia.
Alternative to acetaminophen for fever and pain management when anti-inflammatory action is desired.
Use in pediatric populations for fever and pain with appropriate weight-based dosing.
Treatment of acute gout attacks in some cases.
Use in combination with other drugs for multimodal pain management.
Supportive care in minor surgeries and invasive procedures requiring analgesia.

Side Or Adverse Effects

Gastrointestinal irritation including nausea, dyspepsia, and abdominal pain.
Risk of gastrointestinal bleeding, ulceration, and perforation, particularly in elderly or high-risk patients.
Dizziness and headache as common central nervous system side effects.
Allergic reactions including rash, urticaria, and, rarely, anaphylaxis.
Increased risk of cardiovascular events such as myocardial infarction and stroke with prolonged or high-dose use.
Renal adverse effects including reduced renal perfusion, acute kidney injury, or worsened chronic kidney disease.
Liver function abnormalities and rare cases of hepatotoxicity.
Fluid retention and edema, potentially exacerbating hypertension and heart failure.
Anemia from occult gastrointestinal bleeding.
Photosensitivity reactions are infrequent but possible.
Serious skin reactions such as Stevens-Johnson syndrome are very rare but reported.
Bronchospasm or exacerbation of asthma in aspirin-sensitive individuals.
Potential interactions leading to increased bleeding risk when combined with anticoagulants.
Rare cases of aseptic meningitis reported in susceptible individuals.
Potential for hypersensitivity vasculitis with long-term use.

Precautions

Use the lowest effective dose for the shortest duration to minimize adverse effects.
Caution advised in patients with a history of gastrointestinal ulcers or bleeding.
Monitor renal function during prolonged therapy, especially in elderly or patients with pre-existing renal impairment.
Avoid use in patients with known hypersensitivity to ibuprofen, aspirin, or other NSAIDs.
Assess cardiovascular risk factors prior to initiating therapy; avoid in patients with recent myocardial infarction or stroke unless directed by a physician.
Caution in patients with hypertension, as ibuprofen may exacerbate blood pressure control.
Use cautiously during pregnancy, particularly after 20 weeks gestation due to risks to fetal cardiovascular and renal function.
Evaluate liver function tests before and during treatment in patients with liver disease.
Avoid concurrent use with other NSAIDs to prevent additive toxicity.
Consider the potential for drug interactions with anticoagulants, diuretics, lithium, methotrexate, and corticosteroids.
Advise patients to report signs of gastrointestinal bleeding, chest pain, or allergic reactions promptly.
Use caution in asthma patients due to potential for NSAID-induced bronchospasm.
Avoid in patients with severe heart failure.
Educate patients on proper dosing and adherence to prescribed regimen to avoid overdose.
Instruct patients to avoid alcohol which may increase risk of gastric bleeding.

Warnings

Increased risk of fatal cardiovascular events including heart attack and stroke, particularly with prolonged use or high doses.
Contraindicated immediately before or after coronary artery bypass graft (CABG) surgery due to increased risk of thrombotic events.
Potential for serious gastrointestinal adverse effects including bleeding, ulceration, and perforation that may be fatal.
Risk of severe allergic reactions, including anaphylaxis and angioedema.
May cause kidney damage, especially with chronic use or in patients with existing renal impairment.
Avoid use during the last 20 weeks of pregnancy due to risk of fetal harm including premature closure of the ductus arteriosus.
Risk of liver injury, hence monitoring of hepatic function recommended if used long term.
May exacerbate hypertension or heart failure by promoting sodium and fluid retention.
Potential for blood dyscrasias such as anemia or thrombocytopenia.
Overdose can cause severe gastrointestinal injury including bleeding and perforation.
Use in combination with aspirin may reduce aspirin’s cardioprotective effects if not timed appropriately.
Not recommended in children under 6 months of age without medical advice.
Use may mask signs and symptoms of infection due to anti-inflammatory effects.
Risk of serious skin reactions including Stevens-Johnson syndrome and toxic epidermal necrolysis.
Risk of aseptic meningitis in susceptible individuals.

Contraindication

Known hypersensitivity to ibuprofen or other NSAIDs including aspirin-induced asthma or allergic reactions.
History of NSAID-induced asthma, urticaria, or allergic-type reactions.
Active or history of recurrent gastrointestinal bleeding or ulceration.
Severe heart failure (NYHA III-IV).
Severe hepatic impairment or active liver disease.
Severe renal impairment or kidney failure.
Immediately before or after coronary artery bypass graft surgery.
Third trimester of pregnancy (from 20 weeks gestation onwards).
Children below 6 months of age without medical supervision.
Concomitant use with other NSAIDs for analgesia.
Patients with bleeding disorders or those at high risk of bleeding without medical supervision.
Known hypersensitivity to excipients in specific formulations if applicable.
History of severe skin reactions to NSAIDs.
Use with caution or avoidance in patients with uncontrolled hypertension.
Patients with a history of cerebrovascular bleeding.

Drug Interactions

Concomitant use with anticoagulants (e.g., warfarin) increases risk of bleeding.
Use with corticosteroids (e.g., prednisone) may increase gastrointestinal ulceration risk.
Diuretics and antihypertensive drugs (especially ACE inhibitors and beta-blockers) may have reduced efficacy due to ibuprofen-induced renal effects.
Lithium levels can be increased by ibuprofen leading to lithium toxicity.
Methotrexate clearance may be reduced, increasing risk of toxicity when combined with ibuprofen.
Cyclosporine nephrotoxicity risk is increased when taken with NSAIDs.
Concomitant use with selective serotonin reuptake inhibitors (SSRIs) or other antidepressants may increase bleeding risk.
Aspirin’s antiplatelet effect may be diminished if ibuprofen is taken concomitantly; timing of doses is important.
Phenytoin and sulfonamides protein binding may be displaced by ibuprofen, altering plasma levels.
Concomitant use with other NSAIDs or salicylates increases adverse effect risk.
Potential interaction with herbal supplements that affect coagulation such as ginkgo biloba or garlic.
Avoid combining with alcohol due to additive gastrointestinal risks.
May affect the renal elimination of other drugs eliminated by the kidney.
Caution when used with antihypertensive agents due to possible reduced antihypertensive effect.
Potential pharmacodynamic interactions increasing risk of renal impairment.

Preparations Of The Drug

Oral capsules containing 200 mg of ibuprofen for immediate release.
Oral suspension (liquid) formulations for pediatric use in concentrations of 100 mg/5 mL and 50 mg/1.25 mL.
Immediate release oral tablets available in 100 mg, 200 mg, 400 mg, 600 mg, and 800 mg strengths.
Chewable tablets in 50 mg and 100 mg doses targeting pediatric and patient populations requiring ease of administration.
Multiple branded formulations including Advil, Motrin IB, Midol IB, among others.
Over-the-counter formulations for pain, fever, and inflammation relief.
Prescribed formulations with higher doses for chronic inflammatory conditions.
Liquid-filled soft gel capsules for faster absorption available under select brand names.
Combination products with other analgesics or decongestants in some preparations.
Various generic formulations adhering to established pharmacopeial standards.
Intravenous and lysine salt preparations available for specific hospital use (not covered extensively in this data set).
Different formulations designed for controlled or immediate release as per therapeutic need.
Pediatric formulations with accurate dosing devices such as syringes included.
Packaging designed to ensure stability against moisture and heat; instructions to avoid freezing liquid forms.
Wide availability in pharmacies and retail outlets worldwide with regulatory approval.